Renal cell carcinoma drug and cell therapy: today and tomorrow

Authors

  • Anton A. Pushkin Rostov Oncological Research Institute
  • Yuriy E. Burda Belgorod State National Research University ORCID logo https://orcid.org/0000-0002-1183-4436
  • Aleksandr A. Sevast’yanov Innovative Centre Biruch – New Technologies Ltd
  • Vladimir F. Kulikovskiy Innovative Centre Biruch – New Technologies Ltd
  • Svetlana Yu. Burda Kursk State Medical University
  • Polina A. Golubinskaya Innovative Centre Biruch – New Technologies Ltd
  • Alina K. Zvyagina Innovative Centre Biruch – New Technologies Ltd
  • Natal’ya V. Kulyushina Innovative Centre Biruch – New Technologies Ltd

DOI:

https://doi.org/10.3897/rrpharmacology.4.25251

Abstract

Today, considerable progress in the renal cell carcinoma (RCC) treatment has been made due to development of targeted and immunotherapeutic approaches to the RCC treatment, especially in metastasising carcinoma. In the early stages of RCC, it is possible to use partial or total surgical nephrectomy, but in metastases development, the range of efficient treatment methods is dramatically limited. Appearance of targeted drugs like PD-1 and CTLA-4 receptors and their ligands’ inhibitors in clinical practice has significantly increased the total survival rate of patients with renal cell carcinoma. Emergence of adoptive cell therapy has opened new possibilities and prospects in RCC treatment. Previously activated in vitro cells are used there, which provides antineoplastic activity. For example, it could be antigen-specific cytotoxic T-lymphocytes (CTL), lymphokine-activated natural killers (LAK-NK-cells) and tumour-infiltrating lymphocytes (TILs). In this review, the authors specified the main molecular markers, associated with RCC; and signalling pathways (VEGFR- and EGFR-signalling pathway), which directly take part in carcinogenesis. The paper also looks at clinically applicable targeted immune drugs and the principle of their effect on tumorous cells. Besides, modern clinical studies of cell drugs have been considered. At the moment, there are a number of variants of targeted and immune drugs for the metastatic RCC treatment. Patients have no opportunity to use all the available agents because of their cost and toxicity level. For the most efficient treatment of patients with diagnosed metastatic RCC, it is necessarily to carry out risk stratification and prognostic factors for the response to treatment.

Keywords:

renal cell carcinoma, renal cancer, targeted therapy, immunotherapy, cancer cell therapy, immune system

Author Contribution

Anton A. Pushkin, Rostov Oncological Research Institute

Junior researcher, Rostov Oncological Research Institute, Contribution: collecting information, writing the article

Yuriy E. Burda, Belgorod State National Research University

PhD in Medicine, Supervisor of The Cellular Technologies Project, Innovative Centre Biruch – New Technologies Ltd. (EFKO Group R&D division); Associated Professor at the Department of Pharmacology, Belgorod State National Research University Contribution: providing the concept, editing the article, Scopus

Aleksandr A. Sevast’yanov, Innovative Centre Biruch – New Technologies Ltd

Head of the Molecular-Cellular Technologies Directorate, Innovative Centre Biruch – New Technologies Ltd, Contribution: collecting information

Vladimir F. Kulikovskiy, Innovative Centre Biruch – New Technologies Ltd

Doctor of Medicine Full PhD, MD, Professor, Director of The Institute of Medicine, Contribution: editing the article

Svetlana Yu. Burda, Kursk State Medical University

Student,  contribution: collecting information, translation in English

Polina A. Golubinskaya, Innovative Centre Biruch – New Technologies Ltd

a cell engineer, Cellular Technologies Project, Innovative Centre Biruch – New Technologies Ltd. Contribution: collecting information

Alina K. Zvyagina, Innovative Centre Biruch – New Technologies Ltd

a cell engineer, Cellular Technologies Project, Innovative Centre Biruch – New Technologies
Ltd, contribution: collecting information

Natal’ya V. Kulyushina, Innovative Centre Biruch – New Technologies Ltd

a cell engineer, Cellular Technologies Project, Innovative Centre Biruch – New Technologies Ltd., Contribution: collecting information

Downloads

Published

28-03-2018

How to Cite

Pushkin AA, Burda YE, Sevast’yanov AA, Kulikovskiy VF, Burda SY, Golubinskaya PA, Zvyagina AK, Kulyushina NV (2018) Renal cell carcinoma drug and cell therapy: today and tomorrow. Research Results in Pharmacology 4(1): 17–25. https://doi.org/10.3897/rrpharmacology.4.25251

Issue

Section

Review article

Most read articles by the same author(s)